"Vertex reports long-term results for Casgevy in sickle cell and thalassaemia" was originally created and published by ...

The global CRISPR gene editing market size is calculated at USD 4.77 billion in 2025 and is expected to reach around USD ...

Between Casgevy's long-term potential and the company's innovative pipeline, CRISPR Therapeutics could eventually recover and ...

The United Kingdom has become the first country to give regulatory approval to a medical treatment involving the revolutionary CRISPR gene editing tool.

NHS England estimates that approximately 50 sickle cell disease patients per year will initially receive Casgevy, doubling the current number of patients who undergo stem cell transplants.

Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 ...

Casgevy is manufactured by Vertex Pharmaceuticals, which has been prioritizing winning approval in wealthy countries that are home to only a small fraction of the global sickle cell population.

Drug regulators have approved a CRISPR therapy called Casgevy to treat inherited blood disorders. But what is it and how does it work?

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update ...

Casgevy is one of seven gene therapies and gene-modified cell therapies to have launched on the US market with an average price per unit that is above $1m.

Casgevy is the first treatment to emerge from CRISPR Therapeutics' pipeline, but it probably won't be the last. The company has two off-the-shelf cancer therapies in clinical trials.

The FDA approved Casgevy, a therapy for transfusion-dependent beta thalassemia. Read why investors reacted negatively to the approval, causing a drop in stock prices for VRTX and CRSP.